Literature DB >> 18501530

Does image-guided radiotherapy improve toxicity profile in whole pelvic-treated high-risk prostate cancer? Comparison between IG-IMRT and IMRT.

Hans T Chung1, Ping Xia, Linda W Chan, Eileen Park-Somers, Mack Roach.   

Abstract

PURPOSE: To evaluate the impact of adding image-guided (IG) technique to intensity-modulated radiotherapy (IMRT) on dosimetric avoidance of organs at risk (OAR) and acute toxicities. METHODS AND MATERIALS: A total of 25 consecutively treated patients (10 from National University Hospital and 15 from University of California San Francisco) with high-risk prostate cancer formed the study cohort. All received definitive IMRT with prophylactic nodal RT. Similar IMRT contouring and planning techniques were used at both centers. At the University of California, San Francisco, intraprostatic fiducial markers were used for daily pretreatment on-line corrections (IG-IMRT). In contrast, at the National University Hospital, no fiducial markers were used (IMRT). At the University of California, San Francisco, the planning target volume margins to the prostate were 2-3 mm. At the National University Hospital, they were 1 cm circumferentially, except for 0.5 cm posteriorly. The acute rectal and bladder toxicities and dosimetric endpoints to the planning target volume and organs at risk were compared.
RESULTS: The planning target volume dose coverage was not significantly different between IMRT and IG-IMRT for the prostate, seminal vesicles, and lymph nodes. The volume of rectum and bladder receiving >/=40, >/=60, and >/=70 Gy were all significantly less using IG-IMRT (p <0.001). IG-IMRT yielded lower acute Radiation Therapy Oncology Group Grade 2 rectal (80% vs. 13%, p = 0.004) and bladder (60% vs. 13%, p = 0.014) toxicities.
CONCLUSIONS: IG-IMRT, using daily target localization with fiducial markers, permits the use of smaller margins and correspondingly lower doses to the organs at risk, such as the rectum and bladder. These tangible gains appear to translate into lower clinically significant toxicities.

Entities:  

Mesh:

Year:  2008        PMID: 18501530     DOI: 10.1016/j.ijrobp.2008.03.015

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  34 in total

1.  [Image-guided radiation therapy].

Authors:  J Boda-Heggemann; M Guckenberger; U Ganswindt; C Belka; H Wertz; M Blessing; F Wenz; M Fuss; F Lohr
Journal:  Radiologe       Date:  2012-03       Impact factor: 0.635

Review 2.  Technological advances in radiation therapy for prostate cancer.

Authors:  Mehee Choi; Arthur Y Hung
Journal:  Curr Urol Rep       Date:  2010-05       Impact factor: 3.092

3.  Dosimetric planning study for the prevention of anal complications after post-operative whole pelvic radiotherapy in cervical cancer patients with hemorrhoids.

Authors:  J G Baek; E C Kim; S K Kim; H Jang
Journal:  Br J Radiol       Date:  2015-09-23       Impact factor: 3.039

4.  Toxicity after intensity-modulated, image-guided radiotherapy for prostate cancer.

Authors:  Matthias Guckenberger; Sami Ok; Bülent Polat; Reinhart A Sweeney; Michael Flentje
Journal:  Strahlenther Onkol       Date:  2010-09-30       Impact factor: 3.621

Review 5.  kV cone-beam CT-based IGRT: a clinical review.

Authors:  Judit Boda-Heggemann; Frank Lohr; Frederik Wenz; Michael Flentje; Matthias Guckenberger
Journal:  Strahlenther Onkol       Date:  2011-04-26       Impact factor: 3.621

6.  Intensity-modulated radiotherapy (IMRT) to prostate and pelvic nodes-is pelvic lymph node coverage adequate with fiducial-based image-guided radiotherapy?

Authors:  G Eminowicz; C Dean; O Shoffren; N Macdougall; P Wells; R Muirhead
Journal:  Br J Radiol       Date:  2014-03-20       Impact factor: 3.039

Review 7.  Fiducial marker guided prostate radiotherapy: a review.

Authors:  Angela G M O'Neill; Suneil Jain; Alan R Hounsell; Joe M O'Sullivan
Journal:  Br J Radiol       Date:  2016-09-23       Impact factor: 3.039

8.  Moderate hypofractionated radiotherapy with volumetric modulated arc therapy and simultaneous integrated boost for pelvic irradiation in prostate cancer.

Authors:  C Franzese; A Fogliata; G R D'Agostino; L Di Brina; T Comito; P Navarria; L Cozzi; M Scorsetti
Journal:  J Cancer Res Clin Oncol       Date:  2017-03-08       Impact factor: 4.553

9.  Toxicity and outcome of pelvic IMRT for node-positive prostate cancer.

Authors:  A-C Müller; J Lütjens; M Alber; F Eckert; M Bamberg; D Schilling; C Belka; U Ganswindt
Journal:  Strahlenther Onkol       Date:  2012-10-11       Impact factor: 3.621

Review 10.  Gastrointestinal radiation injury: symptoms, risk factors and mechanisms.

Authors:  Abobakr K Shadad; Frank J Sullivan; Joseph D Martin; Laurence J Egan
Journal:  World J Gastroenterol       Date:  2013-01-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.